This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Leukemias/ Lymphomas  • Immunologic Disorders  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2008;299(5):510-512.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Atlanta—Therapeutic advances in recent years have beaten back and even defeated hematologic cancers in many patients, yet oncologists note that poor prognoses and cancer death rates remain significant. At the 49th Annual Meeting of the American Society of Hematology, held here in December, researchers discussed some of the latest efforts to advance the treatment of hematologic cancers, including Hodgkin and non-Hodgkin lymphomas, leukemia, and multiple myeloma.

"The hematology community is committed to improving patient care and outcomes for malignant diseases of the blood and bone marrow," said Jane Winter, MD, professor, Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago. The research presented at the meeting, she noted, "will have important clinical benefits for patients, including prolonged overall survival and possible cures."

Researchers are testing new agents that attack malignant cells of non-Hodgkin lymphoma and other hematologic cancers. (Photo credit: Cecil H. . . . [Full Text of this Article]

LYMPHOMAS

RELATED LETTERS

Radiopharmaceutical Reimbursement Rates
Jack W. Singer
JAMA. 2008;299(21):2512.
EXTRACT | FULL TEXT  

Radiopharmaceutical Reimbursement Rates—Reply
Tracy Hampton
JAMA. 2008;299(21):2512-2513.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Radiopharmaceutical Reimbursement Rates
Singer
JAMA 2008;299:2512-2512.
FULL TEXT